China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
You may also be interested in...
China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.
Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.